However, while MEK inhibitors have shown clinical efficacy in several types of KRAS-mutated cancers, preclinical studies in CRC revealed that treatment with MEK inhibitor alone was not very effective in KRAS-mutated CRC cells due to different mechanisms of acquired resistance [123,124,125]. This evidence concerns the gene MAP2K7 and cancer.